Tempest Therapeutics, Inc. (TPST) Form 8-K — Aug 13, 2026
$TPSTForm 8-KItems 1.01, 3.02, 9.01Filed Aug 13, 2026, 4:31 PM ET0001193125-26-349334Original filing
Tempest Therapeutics entered into a purchase agreement and registration rights agreement with Lincoln Park Capital Fund on August 13, 2026, under which Lincoln Park committed to purchase up to $50.0 million of Tempest common stock, starting with a $25.0 million initial available amount and stepping up by an additional $25.0 million thereafter.
Key figures
- Shares Offered
- 25000000
- Base price usd
- 1.3854
- Floor price usd
- 0.15
- Exchange cap shares
- 3195881
- Exchange cap percent
- 19.99%
- Facility term months
- 24
- Total commitment usd
- 50000000
- Signing market price usd
- 0.9907
- Initial commitment shares
- 560356
- Nasdaq equity threshold usd
- 2500000
- Additional commitment shares
- 350223
- Beneficial ownership cap pct
- 4.99%
- Initial available amount usd
- 25000000
- Max per regular purchase usd
- 500000
- Regular purchase limit shares
- 60000
- Additional available amount usd
- 25000000
- Regular purchase price discount
- 97% of lower of lowest sale price / 3-lowest-close 10-day average
- Regular purchase price tiers usd
- [1,2]
- Accelerated purchase price discount
- 96% of VWAP
- Regular purchase limit tiers shares
- [70000,80000]
- Accelerated purchase share multiplier
- 300% of regular purchase; 30% of traded volume
Price after filing
1 day: -13.2%7 days: -12.8%30 days: -30.6%
Close on the filing date to close N calendar days later (from $1.17). Historical, not a forecast.
AI analysis
Red flags8 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.